No Data
No Data
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Evercore
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $18
Mizuho Securities analyst Uy Ear maintains $Sage Therapeutics(SAGE.US)$ with a hold rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 40.4%
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Express News | Sage Therapeutics Inc : Mizuho Cuts Target Price to $16 From $18
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET
Analyst Expectations For Sage Therapeutics's Future
In the last three months, 20 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE), offering a diverse range of perspectives from bullish to bearish.The table below provides a snapshot